Key statistics
On Friday, Beam Therapeutics Inc (BEAM:NSQ) closed at 25.05, 20.20% above the 52 week low of 20.84 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.60 |
---|---|
High | 25.43 |
Low | 23.18 |
Bid | 25.78 |
Offer | 26.79 |
Previous close | 23.58 |
Average volume | 1.33m |
---|---|
Shares outstanding | 82.81m |
Free float | 81.63m |
P/E (TTM) | -- |
Market cap | 2.07bn USD |
EPS (TTM) | -1.72 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
- Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
- Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
- Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
- Beam Therapeutics Announces Transition of Chief Financial Officer
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
More ▼